[go: up one dir, main page]

MX2014000373A - Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b. - Google Patents

Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b.

Info

Publication number
MX2014000373A
MX2014000373A MX2014000373A MX2014000373A MX2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A
Authority
MX
Mexico
Prior art keywords
group
influenza
philogenetic
virus
neutralizing
Prior art date
Application number
MX2014000373A
Other languages
English (en)
Other versions
MX346206B (es
Inventor
Theodorus Hendrikus Jacobus Kwaks
David A T M Zuijdgeest
Ronald Vogels
Robert Heinz Edward Friesen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2014000373A publication Critical patent/MX2014000373A/es
Publication of MX346206B publication Critical patent/MX346206B/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a moléculas de enlace, tal como anticuerpos monoclonales humanos, que enlazan a un epítopo en la región del tallo de hemaglutinina del virus de la influenza A del grupo filogenético 1 y grupo 2, así como virus de la influenza B, y tienen actividad neutralizante amplia contra tales virus de la influenza. La descripción proporciona moléculas de ácido nucleico que codifican las moléculas de enlace, sus secuencias y composiciones que comprenden las moléculas de enlace. Las moléculas de enlace pueden usarse en el diagnóstico, profilaxis y/o tratamiento del virus de la influenza A del grupo filogenético 1 y 2, así como virus de la influenza B.
MX2014000373A 2011-07-14 2012-07-12 Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. MX346206B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161572417P 2011-07-14 2011-07-14
EP11173953 2011-07-14
PCT/EP2012/063637 WO2013007770A1 (en) 2011-07-14 2012-07-12 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Publications (2)

Publication Number Publication Date
MX2014000373A true MX2014000373A (es) 2014-03-31
MX346206B MX346206B (es) 2017-03-09

Family

ID=47505543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000373A MX346206B (es) 2011-07-14 2012-07-12 Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.

Country Status (18)

Country Link
US (2) US8961978B2 (es)
EP (1) EP2731967B1 (es)
JP (1) JP5683752B2 (es)
KR (1) KR101941724B1 (es)
CN (1) CN103906763B (es)
AU (1) AU2012282504B2 (es)
BR (1) BR112014000263B1 (es)
CA (1) CA2838999C (es)
DK (1) DK2731967T3 (es)
EA (1) EA027054B1 (es)
ES (1) ES2608321T3 (es)
HR (1) HRP20161740T1 (es)
IL (1) IL230222A (es)
IN (1) IN2014CN00953A (es)
MX (1) MX346206B (es)
MY (1) MY166282A (es)
PH (1) PH12013502479A1 (es)
WO (1) WO2013007770A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP2793945B1 (en) 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
EP3003373A4 (en) 2013-03-14 2016-10-19 Contrafect Corp COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102501920B1 (ko) * 2013-10-02 2023-02-20 메디뮨 엘엘씨 중화 항-인플루엔자 a 항체 및 이의 용도
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
WO2015120097A2 (en) * 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
JP2017512471A (ja) * 2014-03-27 2017-05-25 ジェネンテック， インコーポレイテッド 抗ｂ型インフルエンザウイルス赤血球凝集素抗体及び使用方法
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
CN107074912B (zh) 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
PH12017501216B1 (en) * 2015-02-05 2023-05-24 Janssen Vaccines And Prevention B V Binding molecules directed against influenza hemagglutinin and uses thereof
WO2016124682A1 (en) 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
CN107750253B (zh) 2015-04-08 2022-10-04 达纳－法伯癌症研究所公司 人源化流感单克隆抗体及其使用方法
EP3294753A1 (en) 2015-05-11 2018-03-21 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
JP6867306B2 (ja) 2015-06-01 2021-04-28 メディミューン，エルエルシー 中和抗インフルエンザ結合分子及びその使用
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2018038096A1 (ja) * 2016-08-23 2018-03-01 国立大学法人東京大学 モノクローナル抗体又はその抗原結合フラグメント及びその使用
CN110234337A (zh) 2016-10-27 2019-09-13 扬森疫苗与预防公司 中和流感病毒的化合物
WO2018138681A1 (en) * 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
CA3052353A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
AU2018227440B2 (en) 2017-02-28 2024-06-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JP2020510430A (ja) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターに基づくインフルエンザワクチン
RS63526B1 (sr) 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP2024506000A (ja) 2021-02-04 2024-02-08 四川海思科制▲薬▼有限公司 Ｈａ阻害剤化合物の塩及び結晶形
EP4508077A1 (en) 2022-04-14 2025-02-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
JP2025537776A (ja) 2022-11-14 2025-11-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザｂ型ウイルスワクチン及びその使用
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
US20250090650A1 (en) 2023-09-06 2025-03-20 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026022067A1 (en) 2024-07-20 2026-01-29 Leyden Laboratories B.V. Neutralising antibodies against influenza viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
US9340603B2 (en) * 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b

Also Published As

Publication number Publication date
EA201490288A1 (ru) 2014-05-30
JP5683752B2 (ja) 2015-03-11
US20150274811A1 (en) 2015-10-01
JP2014527403A (ja) 2014-10-16
IN2014CN00953A (es) 2015-04-10
CN103906763B (zh) 2016-10-12
KR20140095017A (ko) 2014-07-31
MY166282A (en) 2018-06-25
BR112014000263A2 (pt) 2017-02-14
ES2608321T3 (es) 2017-04-07
EP2731967B1 (en) 2016-10-12
IL230222A (en) 2017-09-28
EP2731967A1 (en) 2014-05-21
CA2838999C (en) 2021-02-16
KR101941724B1 (ko) 2019-01-23
WO2013007770A1 (en) 2013-01-17
CA2838999A1 (en) 2013-01-17
HRP20161740T1 (hr) 2017-02-10
CN103906763A (zh) 2014-07-02
US9593159B2 (en) 2017-03-14
US8961978B2 (en) 2015-02-24
AU2012282504B2 (en) 2017-07-20
NZ618530A (en) 2016-05-27
PH12013502479A1 (en) 2014-01-20
MX346206B (es) 2017-03-09
AU2012282504A1 (en) 2014-02-06
BR112014000263B1 (pt) 2022-01-18
DK2731967T3 (en) 2017-01-16
US20140120113A1 (en) 2014-05-01
EA027054B1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
MX2014000373A (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b.
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX2011011331A (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
EA201790273A1 (ru) Флагеллиновые композиции и их применение
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
MY175708A (en) Dna antibody constructs and method of using same
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
MX391043B (es) Formulaciones de anticuerpo y metodos.
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
MX387421B (es) Producción de virus en huevos aviares.
MX376962B (es) Nuevos compuestos macrociclicos.
MX378749B (es) Agentes para neutralizacion de influenza.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
EA201491581A1 (ru) Везикулярные композиции
CU20140006A7 (es) Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b

Legal Events

Date Code Title Description
FG Grant or registration